Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech’s drug pipeline.

Amgen has a lot riding on an experimental obesity drug that it hopes will rival those of Eli Lilly and Novo Nordisk. But one ...

Patients with inflammatory bowel disease (IBD) who initially responded to the investigational monoclonal antibody ...

The long-term risk of distant recurrence for women with early breast cancer has declined significantly, a decades-long ...

U.S. Public Interest Research Group, Service Employees International Union (SEIU) and others expressed concerns in a letter ...

Obesity treatment should start at a young age, he said, because if you have overweight at ages 3-6 years, the likelihood of ...

Another local biopharmaceutical company has emerged from stealth mode with several million dollars in financing. Tolerance ...

At the STAT summit, executives discuss their challenges, and hopeful signals, about breaking into markets on obesity and ...

Good Life Advisors LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 17.3% during the third ...

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months. Despite a string of solid earnings reports from the biotechnology giant ...